INCY — Incyte Corp. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Price data
- Price
- $122.83
- YTD price return
- +24.36%
- YTD total return
- +24.36%
- Market cap
- 25B
- Enterprise value
- 21.8B
- Shares outstanding
- 203.8M
- 52W low
- $89.25
- 52W high
- $132.60
- From 52W high
- -7.37%
- From 52W low
- +37.62%
- 52W range
- 77%$89.25–$133
- Beta
- 0.76
Volume
- Rel volume
- 1.85×
- 30D volume
- 1.9M
- 30D $ vol
- 223M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$298K
- Insider net 3M
- −$5.7M
- Insider net 1Y
- −$28.6M
Form 4 transactions by trade date, as filed; latest on file 2026-10-15.
Fundamentals
- Sales (ttm)
- 6B
- Sales/share
- $29.49
- EPS (ttm)
- $1.96
- FCF (ttm)
- 684.9M
- FCF/share
- $3.36
- Book value/share
- $27.68
- Net margin
- 6.71%
- ROE
- 7.15%
- ROA
- 5.54%
- Current ratio
- 3.84
Growth (CAGR, ttm) · 10Y
- Sales
- +24.90%+18.53%+11.21%+19.37%
- Net income
- -66.08%-1.72%-5.48%+10.36%
- FCF
- -42.81%+5.64%+0.36%+14.41%
- Shares
- +3.83%-3.11%-1.59%+0.79%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -66.81%+1.35%-4.04%+9.66%
- Sales/share
- +20.30%+22.34%+13.01%+18.44%
- FCF/share
- -44.92%+9.03%+1.98%+13.55%
- Book value/share
- +16.86%+7.95%+14.20%+30.29%
- Price
- +19.36%+30.79%+12.72%+3.96%
- Total return
- +19.36%+30.79%+12.72%+3.96%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 62.6×
- P/OI (ttm)
- 40.0×
- Fwd P/E
- 14.0×
- P/S (ttm)
- 4.2×
- P/B (mrq)
- 4.4×
- P/FCF (ttm)
- 36.6×
- EV/EBITDA (fy)
- 30.1×
- EV/Sales (ttm)
- 3.6×
- FCF yield (ttm)
- 2.74%
- Buyback yield (realized, 1y)
- -3.83%
- Shareholder yield (realized, 1y)
- -3.83%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/E
- 72nd
- P/OI
- 64th
- P/S
- 35th
- P/B
- 46th
- P/FCF
- 69th
Bar = where today’s multiple sits in INCY’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-04#
Fundamentals#
Operating income
5Y n/m10Y CAGR +40.5%YoY n/mEPS (diluted)
5Y n/m10Y CAGR +71.0%YoY n/mFree cash flow
5Y n/m10Y CAGR +35.8%YoY n/mTTM: operating cash flow $745M, capex −$60.1M
Q3 2026: operating cash flow −$675.3M, capex −$15.6M
Shares (diluted)
5Y −8.0%10Y +7.2%YoY +0.9%Net income
5Y n/m10Y CAGR +69.6%YoY n/mAbout Incyte#
Incyte Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company’s current portfolio centers on hematology, oncology, and inflammation and autoimmunity, with products and programs aimed at treating cancers, blood disorders, and immune-mediated conditions. Incyte Corp. develops both small-molecule medicines and biologics, and its marketed therapies support patients with a range of specialty disease areas, including dermatology and rare hematologic disorders. The company also maintains a pipeline of clinical-stage candidates across its core therapeutic franchises, reflecting its role as a research-driven developer of targeted treatments. Headquartered in Wilmington, Delaware, Incyte Corp. serves healthcare markets in the United States and internationally through its commercial and development activities.
Wilmington, DE·2,844 employees·Biotechnology·incyte.com·As of Oct 28, 2026
Recent filings#
- Oct 29Earnings · Earnings release — EPS −$3.79 vs −$4.27 est. (+11.2%); revenue $1.56B (+14% y/y) 0.1%
- Jul 28Earnings · Earnings release — EPS $2.80 vs $1.76 est. (+59.1%); revenue $1.67B (+38% y/y) 9.3%
ETFs holding INCY#
33 of the 193 ETFs ChartRow carries live hold INCY. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 1.7% |
| XBI | SPDR S&P Biotech ETF | 1.0% |
| VBK | Vanguard Small-Cap Growth ETF | 0.5% |
| COWZ | Pacer US Cash Cows 100 ETF | 0.5% |
| XLV | Health Care Select Sector SPDR Fund | 0.3% |
| VHT | Vanguard Health Care ETF | 0.3% |
| VB | Vanguard Small-Cap ETF | 0.2% |
| RSP | Invesco S&P 500 Equal Weight ETF | 0.2% |
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +24.07% | +0.61% |
| JNJ | Johnson & Johnson | +7.92% | +3.81% |
| ABBV | AbbVie Inc. | +12.18% | +3.09% |
| MRK | Merck & Co. Inc. | +4.20% | +3.93% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +10.08% | +1.22% |
| NVS | Novartis AG | +17.01% | +3.59% |
| TMO | Thermo Fisher Scientific Inc. | +7.84% | +1.12% |
| AMGN | Amgen Inc. | +18.69% | +3.71% |
